Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant vs Hydroxyzine for Aquagenic Pruritus in Myeloproliferative Neoplasms
NCT03808805Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Apr 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprepitant in Aquagenic pruritus (AP), sponsored by Centre Hospitalier Universitaire de Brest. Started Apr 2019; status: completed.
02
Drugs
aprepitant
03
Conditions
Aquagenic pruritus (AP)
Beyond the preview
Go deeper on NCT03808805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808805.